Top Medicare prescribers rake in speaking fees from drugmakers
When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics. So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic's success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic ? even though the drug hadn't proved more effective than competitors. The strategy worked. In the 2012 fiscal year, sales of Bystolic reached $348 million, almost double its total from two years earlier, the company reported.
- mHealth Tackles Readmissions
- 'Kafkaesque' Value System Unfairly Penalizes Doctor Pay
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Targeting Self-Insured Populations
- MA an Insurance Proving Ground for Providers
- Sharp HealthCare Leaves Pioneer ACO Program
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Proton Beam Therapy Poised for Growth in US
- Docs Fret as HHS Addresses Malpractice Reporting 'Loopholes'
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013